Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06769048 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
A Phase 2 study of Geographic Atrophy, sponsored by Boehringer Ingelheim.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06769048 is a Phase 2 study of Geographic Atrophy that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 150 participants, below the 216-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT06769048, a Phase 2 study of Geographic Atrophy, is active but no longer recruiting, sponsored by Boehringer Ingelheim.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose. This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group. Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.
Conditions Studied
Interventions
- DRUG BI 1584862
- DRUG Placebo-matching BI 1584862
Study Locations (20)
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- Global Research Management - Glendale
- Retina Associates of Southern California - Huntington Beach
- Retinal Consultants Medical Group, Inc - Modesto
- Northern California Retina Vitreous Associates MedicalGroup, Inc. - Mountain View
- Eye Research Foundation - Newport Beach
- Retina Consultants of San Diego - Poway
- Retinal Consultants Medical Group - Sacramento
- Bay Area Retina Associates - Walnut Creek - Walnut Creek
Florida
- Vitreo Retinal Associates - Gainesville - Gainesville
- MedEye Associates - Miami
- Eye Associates of Pinellas - Pinellas Park
- East Florida Eye Institute - Stuart
- Center for Retina and Macular Disease - Winter Haven
Arizona
- Associated Retina Consultants - Gilbert
- Associated Retina Consultants, Ltd. - Phoenix
- Cameron Ria, LLC - Phoenix
- Retina Macula Institute of Arizona - Scottsdale
Colorado
- Retina Specialists of Colorado Research, LLC - Denver
Connecticut
- Coastal Eye Surgeons - Greenwich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-01-31 |
| Est. Completion | 2027-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06769048
The ClinicalTrials.gov registry entry for NCT06769048 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 216-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (31% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Geographic Atrophy appearing as the primary indexed condition, and to 2 interventions - of which BI 1584862 is the first listed.
NCT06769048 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06769048 about?
NCT06769048 is a clinical study titled "A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy". This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose. This study ...
What is the current status of trial NCT06769048?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-01-31. Estimated completion is 2027-02-26.
What conditions does trial NCT06769048 study?
This clinical trial studies the following conditions: Geographic Atrophy.
What interventions are being tested in trial NCT06769048?
The interventions under investigation include: BI 1584862 (DRUG), Placebo-matching BI 1584862 (DRUG).
Who is sponsoring clinical trial NCT06769048?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06769048 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
RECRUITING · Phase 2
-
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.